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The HIV-1 tat gene expresses as small regulatory protein plays an essential role in the upregulation 
of viral transcription and elongation of viral transcripts, and is necessary for viral replication.  
Because of its importance, anti-viral reagents that specifically target and inhibit tat function, 
should effectively reduce viral replication. In this study, two anti-tat siRNAs were designed, 
synthesized, and cloned into the retroviral vector, pSuper.retro.neo+GFP. These siRNA constructs, 
designated pSRNGsi5860 and pSRNGsi5892 were subsequently analyzed for their ability to down-
regulate luciferase activity in a tat-dependent assay.  The results indicated that one of these, 
siRNA5892 reduced luicerase expression in a dose-dependent manner. 
Introduction 
Infection by the Human Immunodeficiency virus (HIV-1) 
leads to a gradual loss of immune surveillance due to infection 
and loss of the CD4+ TH lymphocyte population [1-3].  The 
resulting failure of the immune system, concomitant with the 
rise of opportunistic infections, defines the Acquired Immune 
Deficiency Syndrome [4].  The current treatment for HIV-1 
infection is termed HAART or Highly Active Anti-Retroviral 
Treatment and is designed to reduce the viral load by targeting 
two important viral functions: reverse transcription (RT) and 
virus capsid maturation.  Although very effective at reducing 
the viral load, this treatment is not curative.  Importantly, viral 
resistance to these drugs has already developed [5].  
Therefore, it is important that research continue into new 
ways to inhibit viral replication.  Among the possible targets 
for new anti-viral inhibitors are a number of non-enzymatic 
functions encoded by the HIV genome to control the overall 
infection process.  Among these genes are nef, rev, tat, vif, 
vpr, and vpu [6].    
 Tat, or trans-activator of transcription, is a viral regulatory 
gene required for HIV gene expression [7].  The tat protein 
functions by binding to the stem loop of the trans-activation 
response region (TAR), which is transcribed within the first 
60 nucleotides of all HIV mRNAs [8].  The tat/TAR 
interaction promotes the binding of several host transcription 
factors, including Cyclin T and CDK9 [9].  Once recruited to 
the transcription complex, CDK9 hyperphosphorylates the C-
terminal domain of RNA Polymerase II, increasing its 
processivity and allowing efficient elongation of viral 
transcripts [10].  Because tat plays a major role in the viral 
replication process, anti-viral reagents targeting its function 
should inhibit HIV replication. 
 One such group of reagents takes advantage of RNA 
interference.  RNAi is a naturally occurring cellular process 
that is initiated by small, double-stranded RNA molecules that 
trigger degradation of homologous mRNAs and lead to gene 
silencing [11-13].  The RNAi pathway is initiated by 
endogenous or exogenous double-stranded RNAs that are 
acted upon by Dicer, a member of the RNase III family of 
proteins [14].   Dicer cleaves double-stranded RNAs into 
small, ~22 bp siRNA fragments, one strand of which 
associates with the Argonaute protein [15].  The siRNA 
fragment, in association with Argonaute, binds to the target 
mRNA via Watson-Crick base pairing and initiates formation 
of the RISC complex [16], which carries out silencing through 
a number of mechanisms including target RNA degradation.  
It has been shown that siRNAs can be introduced into cells 
exogenously and have been used to specifically silence genes 
in cell culture and in vivo [17-19].  There are several 
advantages to the use of siRNAs to silence gene expression 
including (i) silencing can be mediated by relatively low 
levels of siRNA expression in target cells, (ii) silencing is 
target mRNA specific, (iii) siRNAs are stable in the cell, and 
(iv) siRNAs are not likely to induce interferon responses [20, 
21]. 
 This paper describes the design, cloning, and initial testing 
of two siRNAs targeted to HIV-1 tat mRNA.  These siRNA 
constructs, designated si5860 and si5892 to denote their target 
sequence within the HIV-1 genome, were cloned into the 
retroviral vector, pSuper.retro.neo+GFP.  This unique vector 
was chosen because it was developed to specifically express 
siRNAs from the RNA Polymerase III H1 promoter.  Initial 
testing of these reagents in a transient tat-dependent luciferase 
assay indicated that the activity of one, si5892, acted in a dose 
dependent manner to decrease HIV tat function. 
Materials and Methods 
Oligonucleotides and cloning 
The tat RNA sequence of the HIV-1 genomic clone NL4-3 
(Accession number M19921) was analysed for the presence of 
suitable 19 nucleotide siRNA sites.  This analysis identified 
two such sequences located at nucleotides 5860-5878 and 
5892-5910 (Fig. 1A).  These sequences were used to generate 
two siRNA constructs designated si5860 and si5892 (Fig. 1B).  
Two terminal restriction sites, BglII and HindIII were added, 
and the two complementary strands of each siRNA construct 
were synthesized (si5860 Upper 5’ GAT CCC CTG G AA GCA 
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TCC AG GA AGT CTT CAA GAG AGA CTT CCT GGA TGC TT C 
CAT TTT TA 3’, si5860 Lower 5’ AGC TTA AAA ATG GAA GCA 
TCC AGG AAG TCT CTC TTG AAG ACT TCC TGG ATG CTT 
CCA GGG 3’,  si5892 Upper 5’GAT CCC CTT GTA CCA ATT GCT 
ATT GTT TCA AGA GAA CAA TAG CAA TTG GTA CAA TTT 
TTA 3’ and si5892 Lower 5’AGC TTA AAA ATT GTA CCA ATT 
GCT ATT GTT CTC TTG AAA CAA TAG CAA TTG GTA CAA 
GGG 3’).  
 
A. HIV-1 Tat Exon One 
5830       5840       5850       5860 
atggagccag tagatcctag actagagccc tggaagcatc 
 
5870       5880       5890       5900 
caggaagtca gcctaaaact gcttgtacca attgctattg 
 
5910       5920       5930       5940 
taaaaagtgt tgctttcatt gccaagtttg tttcatgaca 
 
5950       5960       5970       5980 
aaagccttag gcatctccta tggcaggaag aagcggagac 
 
5990       6000       6010       6020 
agcgacgaag agctcatcag aacagtcaga ctcatcaagc 
 
6030       6040 
ttctctatca aagcag 
 
B. Anti-tat si5860 Design 






Figure 1. HIV-1 tat sequence and siRNA design.  (A) The HIV-1 NL4-3 
tat exon 1 provirus sequence was analysed for potential siRNA target 
sites.  This analysis revealed two regions (5860-5878 and 5892-5910) that 
were used to create siRNA constructs.  (B) Using a published model for 
siRNA design (Oligoengine), each 19 nucleotide target sequence was 
used to produce a double-stranded DNA construct.  For this the tat target 
sequence (sense) and its inverted complementary sequence (antisense) 
were connected by a short hairpin sequence.  BglII and HindIII sites (not 
shown) were added to each end of the construct to facilitate cloning into 
the pSuper.retro.neo+GFP vector.  The siRNA shown is targeted to the tat 
RNA sequence at 5860.  A second siRNA, si5892 was similarly designed.  
The sequence located at 6010-6028 was scrambled and used to generate 
the control siRNA construct, pSRNGsiCtrl. 
 
 Each upper and lower oligonucleotide set was combined in 
50 µl Annealing Buffer (100mM NaCl, 50mM HEPES buffer 
(pH 7.4)) and cooled slowly from 90˚C to 4˚C.  Each of the 
resulting siRNA constructs was cloned into the BglII and 
HindIII sites of the retroviral vector pSuper.retro.neo+GFP 
(Oligoengine), which has been shown to effectively express 
siRNAs from an internal RNA Polymerase III H1 promoter 
[22].  In preparation for cloning each siRNA, the pSuper 
plasmid was digested with BglII and HindIII. The digested 
vector fragment was subsequently isolated by gel 
electrophoresis. Ligation reactions were carried out using T4 
DNA Ligase (Promega) at 4ºC overnight.  The ligated 
plasmids were transformed into SURE competent cells 
(Stratagene) and the resulting colonies were analysed for 
siRNA presence.  For this, miniprep DNA [23] was screened 
by PCR using a plasmid-specific primer pair that framed the 
cloning site.  Positive clones were indicated by the presence 
of a 499 bp fragment.  Correct siRNA insertion into the 
resulting plasmids, pSRNGsi5860 and pSRNGsi5892, was 
verified by sequencing. 
Cell lines and transfections  
293T cells were grown in standard medium consisting of 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS), 1% L-glutamine, and 
1% penicillin-streptomycin.  The cells were maintained in a 
humidified 37°C incubator with 5% CO2.  All transfections 
were done by calcium phosphate precipitation based on the 
method of Chen and Okayama [24]. Briefly, 293T cells were 
plated to 50-70% confluency 24 hours prior to transfection. 
The cells were transiently transfected with plasmid DNA in 
125 mM CaCl2, and 2X BBS (280 mM NaCl/ 1.5 mM 
Na2HPO4/ 50 mM N-,N-bis(2-hydroxyethyl)-2-amino-
ethanesulfonic acid)  (pH 7.05)). The plasmid mixture was 
incubated at room temperature for approximately 10 minutes, 
and the entire volume was added to the culture medium.  The 
medium was replaced 24 hours post-transfection, and the cells 
were incubated for a further 24 hours.  Forty-eight hours post-
transfection, the cells were assayed for siRNA activity.  
siRNA-mediated anti-tat activity 
Anti-tat siRNA activity was accessed in transiently 
transfected 293T cells expressing the luciferase reporter gene 
from the HIV-1 genomic clone pNL4-3.Luc.R-.E- [25, 26], 
which is replication incompetent due to two frameshifts that 
rendered the clone env- and vpr-. In addition, the firefly 
luciferase gene was inserted into the pNL4-3 nef gene.  In this 
plasmid, luciferase expression is driven by the HIV-1 
promoter and is therefore tat-dependent.  To determine the 
anti-tat activity of the cloned siRNAs, 293T cells were plated, 
1x106 per well, in 60 mm dishes. After 24 hours, the cells 
were transfected with 2 µg pNL4-3.Luc.R-.E- and either 2 µg 
or 4 µg of pSRNGsi5860, pSRNGsi5892, or pSRNGsiCtrl, a 
previously cloned control siRNA targeted to the scrambled 
HIV-1 tat sequence located at 6010-6028 (Fig. 1A).  These 
transfection mixtures resulted in a 1:1 or 1:2 HIV-1 to siRNA 
plasmid ratio allowing dose-dependent siRNA activity to be 
measured.  Transfection efficiency was analysed 48 hours 
post-transfection by observing GFP expression using an 
Olympus CKX41 inverted microscope with epifluorescence. 
 Luciferase activity was analysed using the Steady-Glo 
Luciferase kit (Promega).  Briefly, 48 hours post-transfection, 
the medium was removed from the transfected cells and 
replaced with 1.1 ml Glo Lysis buffer.  Each plate was rocked 
briefly to ensure complete coverage of the lysis buffer and 
then incubated at room temperature for five minutes.  The cell 
lysate was centrifuged to remove cell debris and aliquoted 
into multiple 1.5 ml tubes.  Protein samples were stored at -
80°C until analysed.  The protein concentration of each 
sample was determined using a BCA protein assay (Pierce), 
and luciferase activity was measured in 50 µg total protein.   
                                             Journal of the South Carolina Academy of Science, [2011], 9(2)   
 
8 
The assay was conducted in a 96-well format and included 
three measurements of each sample taken from two 
independent experiments.  Luciferase activity was reported in 
relative light units (RLU) as measured using a Genios 
luminometer (Tecan). 
Results 
The HIV-1 NL4-3 tat genomic sequence was analysed for the 
presence of potential siRNA target sites. Two sites were 
identified and used to generate siRNA constructs.  The sense 
and antisense strand corresponding to each siRNA was 
synthesized, annealed, and cloned into the retroviral vector, 
pSuper.retro.neo+GFP.  PCR screening was used to identify 
siRNA-positive clones that were subsequently sequenced to 
verify insertion of the specific siRNA construct.  The 
resulting plasmids were designated pSRNGsi5860 and 
pSRNGsi5892.  Successful cloning of si5860 and si5892 
placed each under control of the RNA Polymerase III H1 
promoter (Fig. 2).  In addition, each siRNA vector expresses 
neomycin phosphotransferase and the green fluorescent 
protein (GFP) from a single transcript separated by an internal 
ribosome entry site and under the control of the 
phosphoglycerokinase promoter (Fig. 2). 
 
Figure 2. Generation of anti-tat siRNA retroviral vectors. Two siRNAs 
designed to target the HIV-1 tat mRNA at nucleotides 5860-5878 and 
5892-5910 were synthesized and cloned into the retroviral vector, 
pSuper.retro.neo+GFP.  The pSRNGsi5860 plasmid map is shown.   
 
 To determine the ability of the constructs to inhibit tat 
expression, each siRNA-expression plasmid was co-
transfected into 293T cells along with the HIV-1 genomic 
clone, pNL4-3.Luc.R-.E-.  In this plasmid, luciferase 
expression is under the control of the HIV promoter/enhancer 
and is therefore tat-dependent.  For this assay 293T cells were 
transiently co-transfected with 2 µg of pNL4-3.Luc.R-.E- and 
either 2 µg or 4 µg of pSRNGsi5960, pSRNGsi5892, or 
pSRNGsiCtrl.  Therefore the plasmid ratio of HIV-1 to siRNA 
was either 1:1 or 1:2, allowing a determination to be made 
regarding any dose dependency of the siRNA constructs. 
Transfection efficiency, which was evaluated visually by 
observing GFP expression, suggested that reporter gene 
expression was higher in the 1:2 ratio transfections (Fig.3 B, 
D, and F) as compared to the 1:1 ratio transfections (Fig. 3 A, 
C, and E).  
 
 
Figure  3. Analysis of transfection efficiency. 293T cells were transiently 
transfected with 2 µg pNL4-3.Luc.R-E- and either 2 µg or 4 µg of each 
siRNA-expression plasmid. (A, B). 2 µg and 4 µg pSRNGsiCtrl.  (C, D). 
2 µg and 4 µg pSRNGsi5860.  (E, F).    2 µg and 4 µg pSRNGsi5892.  
Forty-eight hours post-transfection, cells were observed for GFP 
expression as an indication of transfection efficiency.  This analysis 
indicated efficient transfection and suggested increased GFP expression 
in cells transfected at the 1:2 plasmid ratio.  
 To measure luciferase activity, transfected cells were lysed 
to obtain total cytoplasmic protein. Six 50 µg total protein 
samples, three samples taken from each of two independent 
experiments, were analysed to determine the relative 
luciferase activity associated with each HIV-1/siRNA plasmid 
combination.  The results of these tests indicated that si5892 
was active against tat in a dose dependent manner (Fig. 4, 
pSRNGsi5892).  To this end,  293T cells transfected at a 1:2 
HIV-1/5892siRNA plasmid ratio showed a significantly lower 
luciferase activity than identical cells transfected at a 1:1 
HIV-1/5892 siRNA ratio (p = 0.002).  In comparison, 293T 
cells transfected at a 1:2 HIV-1/5860siRNA plasmid ratio did 
not indicate significantly different luciferase activity as 
compared to the cells transfected at a 1:1 HIV-1/si5860 
plasmid ratio.  However, luciferase activity at the 1:2 plasmid 
ratio trended lower than that of the 1:1 plasmid ratio (Fig. 4, 
pSRNGsi5860).  Additionally, the control siRNA 




Figure 4. Anti-tat siRNA luciferase assay. 293T cells were transiently 
transfected with 2 µg of the HIV-1 genomic clone pNL4-3.Luc.R-.E- and 
either 2 µg or 4 µg of the siRNA-expression plasmids, pSRNGsiCtrl, 
pSRNGsi5860, or pSRNGsi5892.  Luciferase activity was measured 48 
hours post-transfection in transfected cell lysates.   This analysis indicated 
a significant dose dependent decrease in luciferase activity as a function 
of pSRNGsi5892 plasmid levels (p = 0.002).  No significant differences 
in luciferase activity were observed with pSRNGsiCtrl or pSRNGsi5860.  
                                                                                                           Journal of the South Carolina Academy of Science, [2011], 9(2)   
 
9 
Each measurement represents the mean and standard error from six 
samples taken from two independent experiments.   
Conclusions 
The primary goal of this project was to design and clone two 
siRNA constructs targeted to HIV-1 tat.  Subsequently, an 
analysis of the HIV-1 tat genomic sequence revealed two 
potential siRNA target sites located at nucleotides 5860-5878 
and 5892-5910, respectively (Fig. 1).  To determine which of 
these sequences provides a more attractive target, each of the 
19-nucleotide sequences was integrated into a siRNA model 
based on the Oligoengine design for cloning into their 
retroviral vector, pSuper.retro.neo+GFP.   The resulting DNA 
oligonucleotides were synthesized and cloned to create the 
siRNA constructs, pSRNGsi5860 and pSRNGsi5892 (Fig 2.)  
 The relative anti-tat activity of these siRNA constructs was 
tested in a transient assay in which each was co-transfected 
along with the HIV-1 genomic clone, pNL4-3.Luc.R-.E-.  In 
this plasmid, luciferase expression is under control of the 
HIV-1 promoter and is therefore tat-dependent.  Co-
transfections with pNL4-3.Luc.R-.E- and the siRNA plasmids 
at either a 1:1 or a 1:2 plasmid ratio indicated that one si5892, 
acted in a dose dependent manner to reduce luciferase activity 
(Fig. 4).  In comparison, si5860, showed no significant ability 
to reduce luciferase activity in a dose-dependent manner. 
 Co-transfection of pNL4-3.Luc.R-.E- with anti-tat reagents, 
such as the siRNA constructs described here, provides a 
convenient and relatively simple assay to determine the 
effectiveness of such reagents without the need for more 
elaborate methods.  However, because this is an indirect 
measure of anti-tat activity, follow-up analyses must be made 
to verify these results.  There are a number of factors that may 
impact the relative activity of the siRNAs in this system.  
Primarily, the transient nature of the experiment makes it 
difficult to control plasmid uptake by the transfected cells.  It 
is likely that some cells have altered HIV-1/siRNA plasmid 
ratios.  However, the variation among the samples was 
relatively small, indicating that this assay is a reasonable 
system for initial screening of anti-HIV siRNAs.  In addition 
to determining if either siRNA construct act directly on tat, it 
will also be important to test the ability of the pSuper vectors 
to generate retroviral particles to deliver the siRNA 
constructs.  These assays will allow a more realistic check of 
siRNA activity and potential efficacy. 
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